Novel Inhibitors of Checkpoint Kinase 1

Inhibition of Chk1 kinase has garnered attention as a possible complement to DNA‐damaging chemotherapeutic agents, widening their therapeutic window. As a result, several distinct classes of Chk1 inhibitors have been recently identified with selected compound advancing to clinical trials stage. This...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2007-11, Vol.2 (11), p.1571-1585
Main Authors: Arrington, Kenneth L., Dudkin, Vadim Y.
Format: Article
Language:English
Subjects:
Animals
cancer
Cell Cycle - drug effects
Cell Line, Tumor
Checkpoint Kinase 1
chemotherapeutics
Chk1
DNA Damage
Humans
Phosphorylation
Protein Kinase Inhibitors - pharmacology
Protein Kinases - drug effects
Protein Kinases - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhibition of Chk1 kinase has garnered attention as a possible complement to DNA‐damaging chemotherapeutic agents, widening their therapeutic window. As a result, several distinct classes of Chk1 inhibitors have been recently identified with selected compound advancing to clinical trials stage. This review focuses on the challenges and recent progress achieved in this area from a medicinal chemistry perspective.
ISSN:1860-7179
1860-7187
DOI:10.1002/cmdc.200700131